Compared to metformin and other diabetes medications, the reduction ranged from 38-55% and even compared to earlier generation GLP-1RAs (albiglutide, dulaglutide, exenatide, liraglutide, and lixisenatide), semaglutide showed a 34-38% reduction
However, enhancing the endogenous secretion of GLP-1 through dietary, microbial, or pharmacological stimuli represents a promising complementary strategy
Patients who received bimagrumab alone saw a 2.5% increase in muscle mass
Eli Lilly, the pharmaceutical company developing retatrutide, has progressed the compound into Phase 3 clinical trials, which are evaluating its efficacy and safety in larger populations across multiple indications, including obesity and type 2 diabetes